Literature DB >> 6328147

Interaction of dextrorotatory opioids with phencyclidine recognition sites in rat brain membranes.

T F Murray, M E Leid.   

Abstract

The potencies of several dextrorotatory opioids, including four pairs of enantiomers, as inhibitors of specific [3H]PCP binding to rat brain synaptic membranes has been determined. Of the compounds tested unlabeled phencyclidine (PCP) was the most potent followed by (-)-cyclazocine greater than dextrorphan greater than (+) ketamine greater than (+) cyclazocine greater than (+)- SKF10 ,047 greater than levorphanol greater than dextromethorphan greater than (-) SKF10 ,047 greater than (-)-ketamine greater than (+/-) pentazocine and greater than (+/-) ethylketocyclazocine. The opiate mu receptor ligands, morphine, naloxone and naltrexone were virtually inactive as competitors of specific [3H]PCP binding. Unlike the stereostructural requirements for opiate mu receptors where activity resides predominantly in the levorotatory enantiomers, the present results support the contention that binding to the [3H]PCP labeled recognition site may reside in either the levorotatory or the dextrorotatory enantiomer. The specific binding of [3H]PCP which was defined as total binding minus that occurring in the presence of 10 microM dextrorphan was found to be of a high affinity, saturable, reversible and sensitive to thermal degradation. These results suggest that certain dextrorotatory morphinan derivatives may prove to be useful probes in further investigations of the molecular characteristics of the [3H]PCP binding site in brain membrane preparations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6328147     DOI: 10.1016/0024-3205(84)90121-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Comparative effects of dextromethorphan and dextrorphan on nicotine discrimination in rats.

Authors:  M Jerry Wright; Robert E Vann; Thomas F Gamage; M Imad Damaj; Jenny L Wiley
Journal:  Pharmacol Biochem Behav       Date:  2006-11-16       Impact factor: 3.533

Review 2.  Neuropsychopharmacological understanding for therapeutic application of morphinans.

Authors:  Eun-Joo Shin; Jau-Shyong Hong; Hyoung-Chun Kim
Journal:  Arch Pharm Res       Date:  2010-10-30       Impact factor: 4.946

Review 3.  Ketamine and phencyclidine: the good, the bad and the unexpected.

Authors:  D Lodge; M S Mercier
Journal:  Br J Pharmacol       Date:  2015-07-28       Impact factor: 8.739

4.  High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.

Authors:  Chad J Reissig; Lawrence P Carter; Matthew W Johnson; Miriam Z Mintzer; Margaret A Klinedinst; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2012-04-13       Impact factor: 4.530

5.  Co-administration of dextromethorphan with morphine attenuates morphine rewarding effect and related dopamine releases at the nucleus accumbens.

Authors:  Eagle Y-K Huang; Te-Chen Liu; Pao-Luh Tao
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-15       Impact factor: 3.000

6.  Discriminative stimulus effects of dextromethorphan in the rat.

Authors:  S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1994-11       Impact factor: 4.530

7.  Psychotomimetic sigma-ligands, dexoxadrol and phencyclidine block the same presynaptic potassium channel in rat brain.

Authors:  D K Bartschat; M P Blaustein
Journal:  J Physiol       Date:  1988-09       Impact factor: 5.182

8.  A comparison of the binding of sigma opioids and phencyclidine, and the interaction with antipsychotic drugs in rat brain membranes.

Authors:  C P Downes; P E Lewis; M A Stone
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.